Genetic Analysis, a diagnostic company within Life Science, is growing rapidly. To continue its expansion, the company needs to raise capital, expected to be done in several steps. First, in a direct issue to a group of existing shareholders, followed by a repair rights issue directed to existing shareholders. Its partner in
The third quarter was soft due to earlier stock-building at larger customers. Sales increased by 17 percent to
Estimates has been adjusted for coming years. In 2023, growth is expected to increase to 32 percent before accelerating in 2024 and 2025. Mangold use a DCF model to value the company, full dilution of upcoming shares is considered. This gives a new target price set to
http://publish.ne.cision.com//Release/ViewReleaseHtml/72E0249C47895C6BE0C856B0705FC7D6
https://mb.cision.com/Main/20846/3876825/2433829.pdf
(c) 2023 Cision. All rights reserved., source